A U Sabitov, D A Lioznov, K V Zhdanov, E P Tikhonova, E V Esaulenko, O P Kovtun, P L Kuznetsov, P V Sorokin
{"title":"[Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19].","authors":"A U Sabitov, D A Lioznov, K V Zhdanov, E P Tikhonova, E V Esaulenko, O P Kovtun, P L Kuznetsov, P V Sorokin","doi":"10.26442/00403660.2024.05.202770","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults.</p><p><strong>Materials and methods: </strong>The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.</p><p><strong>Results: </strong>The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.</p><p><strong>Conclusion: </strong>As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2024.05.202770","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults.
Materials and methods: The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.
Results: The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.
Conclusion: As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
